Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Feb 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-01-28

Reporting Person: Sullivan Timothy Eugene (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-28	Common Stock	A	7500	—	Acquired	31369	Direct
2021-01-28	Common Stock	A	3750	—	Acquired	35119	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-28	Stock Option (Right to Buy)	$44.90	A	45000	Acquired	2031-01-27	Common Stock (45000)	Direct
2021-01-28	Stock Option (Right to Buy)	$44.90	A	22500	Acquired	2031-01-27	Common Stock (22500)	Direct

Footnotes

F1: This Restricted Stock Units grant will vest 25% annually over four years from grant date, subject to continued service.

F2: Includes 482 shares from 4/30/20 ESPP Purchase.

F3: This Performance Unit grant will vest 25% annually over four years from grant date, subject to the satisfaction of a specified performance condition and continued service.

F4: This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F5: This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.